IDegLira

01/01/2023 - "A Randomized Controlled Trial Comparing the Efficacy and Safety of IDegLira Versus Basal-Bolus in Patients With Poorly Controlled Type 2 Diabetes and Very High HbA1c ≥9-15%: DUAL HIGH Trial."
09/28/2023 - "IDegLira for type 2 diabetes: a systematic review and meta-analysis."
09/01/2023 - "Retrospective Study of IDegLira, a New Fixed-Ratio Combination, in Japanese Patients With Type 2 Diabetes Mellitus: Analysis of Background Factors Affecting Effectiveness After 6 Months of Treatment."
02/01/2023 - "Switching to IDegLira offers effective treatment intensification for type 2 diabetes patients with inadequate glycaemic control."
08/01/2022 - "IDegLira for the Real-World Treatment of Type 2 Diabetes in Italy: Protocol and Interim Results from the REX Observational Study."

12/01/2021 - "Notably, no patient reported episodes of severe hypoglycemia after initiation of iDegLira treatment. "
01/01/2019 - "However, cost of control values were substantially lower with IDegLira when the more stringent target of HbA1c ≤6.5% was used, and when patient-centered outcomes of hypoglycemia risk and impact on weight were included. "
04/01/2017 - "There were no episodes of severe hypoglycemia during treatment with IDegLira. "
02/01/2017 - "Rates of confirmed hypoglycemia were low, but higher with IDegLira versus unchanged GLP-1RA. "
12/01/2015 - "Confirmed hypoglycemia rate was 122.8 (90.7; 166.1), 1060.8 (680.2; 1654.4), and 286.1 (231.1; 354.1) events/100 patient-years for IDegLira, BB, and up-titrated IGlar, respectively. "

01/01/2021 - "However, a lower weight gain is obtained with iDegLira compared to iDeg (-2.2 to -2.5 Kg), iGlar (-1.7 to -3.2 Kg), and basal-bolus (-3.6 Kg) as well as with iGlarLixi compared to iGlar (-1.4 Kg). "
01/01/2020 - "After 26 weeks, glycated haemoglobin (HbA1c) reductions were greater with IDegLira versus IGlar U100 (-21.5 vs. -16.4 mmol/mol [-2.0 vs. -1.5%]), as was the percentage of participants achieving HbA1c <53 mmol/mol (78.7% vs. 55.7%) and HbA1c targets without weight gain and/or hypoglycaemia. "
01/01/2018 - "The majority (70%) of respondents prescribe IDegLira in the same visit they first mention it, with uncontrolled glycated hemoglobin (HbA1c) (44%) and weight gain (22%) being the most common reasons. "
01/01/2023 - "In participants with T2D and HbA1c ≥9.0-15.0%, IDegLira resulted in similar HbA1c reduction, less hypoglycemia, and less weight gain compared with the basal-bolus regimen."
01/01/2023 - "IDegLira resulted in significantly lower rates of hypoglycemia <70 mg/dL (26% vs. 48%, P = 0.008; odds ratio 0.39, 95% CI 0.19, 0.78), and less weight gain (1.24 ± 8.33 vs. 5.84 ± 6.18 kg, P = 0.001; ETD -4.60, 95% CI -7.33, -1.87). "

01/01/2020 - "IDegLira initiation resulted in improved HbA1c and weight loss. "
02/01/2023 - "Our results showed that more patients with iDegLira had HbA1c less than 7% and these combination had better effect on weight loss. "
09/14/2022 - "IDegLira treatment was associated with weight loss compared with gain for ICT (MD 6.7 kg, 95% CI 5.0-8.5). "
11/01/2014 - "Mean weight reduction with IDegLira was 2.7 kg vs. no weight change with IDeg, P < 0.0001. "
09/14/2022 - "Treatment with IDegLira over 18 months resulted in greater HbA1c reductions, weight loss versus gain, and a lower rate of hypoglycaemia versus ICT in people with type 2 diabetes."

08/01/2020 - "After 12 months, 84% of patients were persistent on IDegLira, with improved glycaemic control and reductions in body weight."
12/01/2015 - "At end of study, differences between IDegLira and BB or up-titrated IGlar, respectively, were as follows: reduction in HbA1c -0.30%, 95% confidence interval (-0.58; -0.01) and -0.65% (-0.83; -0.47); change in body weight -6.89 kg (-7.92; -5.86) and -4.04 kg (-4.69; -3.40) all in favor of IDegLira. "
02/01/2023 - "Change in body weight was significant in iDegLira group (1.8 kg vs. 0.7 kg, p < 0.001). "
04/01/2018 - "Body weight was reduced by 1.42 [95% CI = 0.35-2.50] kg with IDegLira compared with iGlarLixi. "
01/01/2018 - "Body weight decreased with IDegLira and increased with basal-bolus (ETD -3.6 kg [95% CI -4.2, -2.9]). "